---
title: eBook - Protein biomarkers in practice
description: Drug development is high-risk, with critical decisions often made without sufficient translational insight—leading to highly costly delays and late-stage failures. Olink protein biomarkers change this dynamic.
image: https://info.olink.com/hubfs/olink-application-biomarker_discovery_to_clinical_utility.jpg
---

[![Olink.png](https://info.olink.com/hs-fs/hubfs/00%20-%20Campaign%20Assets/23-10%20Master%20Folder/Logos/Olink-Logotype_Black.png?width=1000&height=304&name=Olink-Logotype_Black.png "Olink.png")](http://olink.com)

## EBOOK

 Protein biomarkers in practice: Strategies to reduce drug development risk

 Discover how leading pharma experts are using biomarker-driven strategies in these 7 case studies

DOWNLOAD EBOOK

## About this eBook

Drug development is high-risk, with critical decisions often made without sufficient translational insight—leading to highly costly delays and late-stage failures.

Olink protein biomarkers change this dynamic.

In *Protein Biomarkers in Practice: Strategies to Reduce Drug Development Risk*, discover how pharma teams use Olink high-specificity proteomics to strengthen target validation, enable earlier go/no-go decisions, and optimize patient selection across the pipeline.

Learn how Olink proteomics biomarkers have been adopted by your peersto reduce uncertainty, improve trial efficiency, and deliver actionable biological insight from every sample—providing the translational backbone to de-risk development.

 

**Case study 1:** Multiomic Integration Strengthens Causal Target Discovery in Ischemic Heart Disease

**Case study 2:** Improving Safety and Toxicity Biomarkers for Cancer Combination Therapies

**Case study 3:** Reverse Translation in Action: Using Proteomics to Decode Clinical Response to IL-6 Blockade

**Case study 4:** Maximizing Sample Value: Unlocking Deep Proteomic Insight from Precious Clinical Specimens

**Case study 5:** Early Efficacy Evaluation: Enabling Faster, Informed Go/No-Go Decisions

**Case study 6:** Molecular Patient Segmentation: Enriching Trials Through Proteomic Stratification

**Case Study 7:** Non-Invasive Endpoints: Reducing Patient Burden and Improving Recruitment in Alzheimer’s Disease

 

© 2026 Olink Proteomics AB, part of Thermo Fisher Scientific. Olink products and services are For Research Use Only. Not for use in diagnostic procedures.